These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 24619898

  • 1. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
    Sezer S, Tutal E, Bal Z, Uyar ME, Bal U, Cakir U, Acar NO, Haberal M.
    Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
    [Abstract] [Full Text] [Related]

  • 2. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D.
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
    Večerić-Haler Ž, Romozi K, Antonič M, Benedik M, Ponikvar JB, Ponikvar R, Knap B.
    Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.
    Ren Fail; 2012 Jun; 34(3):297-303. PubMed ID: 22251408
    [Abstract] [Full Text] [Related]

  • 5. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
    Thadhani RI, Rosen S, Ofsthun NJ, Usvyat LA, Dalrymple LS, Maddux FW, Hymes JL.
    Clin J Am Soc Nephrol; 2020 Mar 06; 15(3):384-391. PubMed ID: 32111702
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.
    J Nephrol; 2009 Mar 06; 22(1):59-68. PubMed ID: 19229819
    [Abstract] [Full Text] [Related]

  • 7. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH, Saidin R, Loo CY, Mohd R, Zainudin S, Shah SA, Norella KC.
    Nephrology (Carlton); 2009 Aug 06; 14(5):488-92. PubMed ID: 19298641
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS, Karagiannis PC, Peyerl FW.
    J Manag Care Pharm; 2007 Jun 06; 13(5):397-411. PubMed ID: 17605511
    [Abstract] [Full Text] [Related]

  • 9. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C, Maresca G, Distasio E, Cacaci S, Panocchia N, Luciani G, Bossola M.
    Hemodial Int; 2011 Jan 06; 15(1):69-78. PubMed ID: 21223484
    [Abstract] [Full Text] [Related]

  • 10. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Jan 06; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 11. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Kumar J, Tran NT, Schomberg J, Streja E, Kalantar-Zadeh K, Pahl M.
    J Ren Nutr; 2016 Jul 06; 26(4):265-9. PubMed ID: 27038806
    [Abstract] [Full Text] [Related]

  • 12. Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis.
    Liu X, Liu Y, Zheng P, Xie X, Li Z, Yang R, Jin L, Mei Z, Chen P, Zhou L.
    Eur J Clin Pharmacol; 2024 Oct 06; 80(10):1555-1569. PubMed ID: 39002024
    [Abstract] [Full Text] [Related]

  • 13. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
    Mittman N, Desiraju B, Meyer KB, Chattopadhyay J, Avram MM.
    Kidney Int Suppl; 2010 Aug 06; (117):S33-6. PubMed ID: 20671742
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP, Mazzaferro S, Brancaccio D, Cannella G, Messa P, Di Luca M, Morosetti M, Costanzo AM, di Luzio Paparatti U, Cornago D, Cozzolino M, FARO Study Group.
    J Med Econ; 2012 Aug 06; 15(6):1110-7. PubMed ID: 22702445
    [Abstract] [Full Text] [Related]

  • 15. Use of 3-hour daily hemodialysis and paricalcitol in patients with severe secondary hyperparathyroidism: A case series.
    Achinger SG, Mizani MR, Ayus JC.
    Hemodial Int; 2010 Apr 06; 14(2):193-9. PubMed ID: 20337743
    [Abstract] [Full Text] [Related]

  • 16. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
    Koc H, Hoser H, Akdag Y, Kendir C, Ersoy FF.
    Int Urol Nephrol; 2019 Jul 06; 51(7):1261-1270. PubMed ID: 31161518
    [Abstract] [Full Text] [Related]

  • 17. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.
    Cozzolino M, Galassi A, Gallieni M, Brancaccio D.
    Curr Vasc Pharmacol; 2008 Apr 06; 6(2):148-53. PubMed ID: 18393917
    [Abstract] [Full Text] [Related]

  • 18. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M.
    Ther Apher Dial; 2015 Jun 06; 19(3):225-34. PubMed ID: 25363733
    [Abstract] [Full Text] [Related]

  • 19. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, Shah SA.
    Clin Exp Nephrol; 2014 Jun 06; 18(3):507-14. PubMed ID: 23903802
    [Abstract] [Full Text] [Related]

  • 20. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F, Yudd M.
    Am J Kidney Dis; 2001 Nov 06; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.